OBJECTIVE: To explore the application of cervical cancer screening system, TruScreen in detecting atypical squamous cell of undetermined significance (ASCUS) patients. METHODS: A total of 42 cases were selected, who were diagnosed as ASCUS by thinprep cytologic test (TCT). Area from site 15 to 20, site 21 to 32 were detected by TruScreen. And the result was compared with those of cases which had positive pathological result of cervical biopsy. RESULTS: There were 16 cases with abnormal pathological result in ASCUS cases, including 6 cases with cervical intraepithelial neoplasia (CIN) I, 6 cases with CIN II, 3 cases with CIN III and 1 case with infiltrating carcinoma. The consistency between TCT and pathological test was 38.10% (16/42). The positive rate of TruScreen at site 15-20 was 61.91% (26/42). There was significant difference in consistency with pathological test between TCT and TruScreen (x(2)=4.762, P=0.029). The positive rate of TruScreen at site 21-32 was 66.67% (28/42)(Kappa=0.181, P=0.016). There was significant difference in consistency with pathological test between TCT and TruScreen (x(2)=9.4919, P=0.002). And no case was missed when site 21-32 of patients with CINII and above were detected by TruScreen. CONCLUSIONS: TruScreen is effective in detecting ASCUS patients.
OBJECTIVE: To explore the application of cervical cancer screening system, TruScreen in detecting atypical squamous cell of undetermined significance (ASCUS) patients. METHODS: A total of 42 cases were selected, who were diagnosed as ASCUS by thinprep cytologic test (TCT). Area from site 15 to 20, site 21 to 32 were detected by TruScreen. And the result was compared with those of cases which had positive pathological result of cervical biopsy. RESULTS: There were 16 cases with abnormal pathological result in ASCUS cases, including 6 cases with cervical intraepithelial neoplasia (CIN) I, 6 cases with CIN II, 3 cases with CIN III and 1 case with infiltrating carcinoma. The consistency between TCT and pathological test was 38.10% (16/42). The positive rate of TruScreen at site 15-20 was 61.91% (26/42). There was significant difference in consistency with pathological test between TCT and TruScreen (x(2)=4.762, P=0.029). The positive rate of TruScreen at site 21-32 was 66.67% (28/42)(Kappa=0.181, P=0.016). There was significant difference in consistency with pathological test between TCT and TruScreen (x(2)=9.4919, P=0.002). And no case was missed when site 21-32 of patients with CINII and above were detected by TruScreen. CONCLUSIONS: TruScreen is effective in detecting ASCUS patients.